

ASX ANNOUNCEMENT

NOTES TO APPENDIX 4C

SYDNEY, Tuesday, 26 July 2016: Cellmid Limited (ASX: CDY) provides the following Notes to the Appendix 4C for the fourth quarter of FY2016.

Cellmid closed the fourth quarter of FY2016 with a cash balance of over \$2.67 million, reporting solid cash receipts from customers of \$1.47 million, up 270% compared with the same period last year (\$545K in 4Q2015).

Net operating cash outgoings have been reduced to \$232K during the quarter, down from \$1.29 million in the previous quarter. Advangen Japan, Cellmid's wholly owned subsidiary, was cash flow positive during the quarter and is expected to report an operational profit for the FY2016 financial year.

The most significant expenditure during the quarter related to staff costs, which represent the Company's efforts to replace the contract team with its own sales force. This has started to show benefits such as increased pharmacy training sessions, better stocking levels, transparent reporting and more responsive service to our customers. Overall sell-through in pharmacies has improved significantly as a result even though advertising was limited to digital media during the quarter.

Cellmid formed a distribution partnership in July 2016 with Colour Collective to sell its evolix® branded hair growth products in the USA. The partnership is the culmination of more than six months of product and business development activity. Cellmid applied a substantial amount of its capital during the last two quarters of FY2016 to complete product development in preparation for the USA launch.

In June 2016 Cellmid received \$94K as royalty payment for the half year from Pacific Edge from sales of their CxBladder® bladder cancer diagnostic products.


During the 2016 financial year Cellmid had \$3.89 million cash receipts from customers and had net operational cash outflows of \$2.5 million. Further update on the financial year results will be provided during the investor call on Wednesday, 27th July 2016 (ASX announcement 21 July 2016).

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

Cellmid Limited

ABN

69 111 304 119

Quarter ended ("current quarter")

30 June 2016

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	1,474	3,883
1.2 Payments for		
(a) staff costs	(706)	(2,193)
(b) advertising & marketing	(309)	(1,613)
(c) research & development	(294)	(1,790)
(d) leased assets	-	-
(e) other working capital	(402)	(1,836)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	7	40
1.5 Interest and other costs of finance paid	(2)	(128)
1.6 Income taxes paid	-	(11)
1.7 Other - R&D Tax Concession	-	1,122
Net operating cash flows	(232)	(2,526)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	(232)	(2,526)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	(1)
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(7)	(18)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	(7)	(19)
1.14 Total operating and investing cash flows	(239)	(2,545)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	3,726
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	228
1.18 Repayment of borrowings	(19)	(341)
1.19 Dividends paid	-	-
1.20 Other (provide details if material)	-	-
Net financing cash flows	(19)	3,613
Net increase (decrease) in cash held	(258)	1,068
1.21 Cash at beginning of quarter/year to date	2,929	1,583
1.22 Exchange rate adjustments	17	37
1.23 Cash at end of quarter	2,688	2,688

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	40
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

The amount disclosed is all payments made to directors and related parties during the quarter. The full amount is included in 1.2(a).

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

NIL

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

NIL

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	1,036	1,036
3.2	Credit standby arrangements	N/A	N/A

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	2,688	2,929
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	2,688	2,929

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration	N/A	N/A
5.3 Consideration for Acquisition or disposal	N/A	N/A
5.4 Total net assets	N/A	N/A
5.5 Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



(Director/Company secretary)

Print name: Maria Halasz

Date: 26 June 2016

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.